DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Group 1 - Faruqi & Faruqi, LLP is investigating potential claims against Tvardi Therapeutics, Inc. following significant losses suffered by investors [2][4] - The law firm encourages investors who experienced substantial losses in Tvardi stock or options to discuss their legal rights [1][4] - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4] Group 2 - Moonlake Immunotherapeutics' shares dropped over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis [5] - The trial aimed to evaluate safety, pharmacokinetics, and exploratory outcomes related to lung function, but did not meet its goals according to the company's assessment [5] - Preliminary data indicated that baseline characteristics of patients were similar across treatment arms, except for a lower percent predicted Forced Vital Capacity (FVC) in placebo-treated patients compared to those treated with TTI-101 [5]